Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email


Check back regularly for news, coverage, and announcements about MAVA.


Cambridge-based Epizyme Files to Raise $69 Million in IPO, NEA an Investor

Epizyme, a Cambridge-based biopharmaceutical company, has filed with the Securities and Exchange Commission for its initial public offering of stock to raise an estimated $69 million. Founded in late 2007, Epizyme is focused on researching treatments for blood cancer and tumors. Investors in the company include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital, Kleiner Perkins Caufield & Byers, New Enterprise Associates, and GlaxoSmithKline.

Read More